269 related articles for article (PubMed ID: 33647515)
1. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study.
López-Medrano F; Pérez-Jacoiste Asín MA; Fernández-Ruiz M; Carretero O; Lalueza A; Maestro de la Calle G; Caro JM; de la Calle C; Catalán M; García-García R; Martínez-López J; Origüen J; Ripoll M; San Juan R; Trujillo H; Sevillano Á; Gutiérrez E; de Miguel B; Aguilar F; Gómez C; Silva JT; García-Ruiz de Morales D; Saro-Buendía M; Marrero-Sánchez Á; Chiara-Graciani G; Bueno H; Paz-Artal E; Lumbreras C; Pablos JL; Aguado JM;
Int J Infect Dis; 2021 Apr; 105():487-494. PubMed ID: 33647515
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness.
Rubio-Rivas M; Ronda M; Padulles A; Mitjavila F; Riera-Mestre A; García-Forero C; Iriarte A; Mora JM; Padulles N; Gonzalez M; Solanich X; Gasa M; Suarez-Cuartin G; Sabater J; Perez-Fernandez XL; Santacana E; Leiva E; Ariza-Sole A; Dallaglio PD; Quero M; Soriano A; Pasqualetto A; Koo M; Esteve V; Antoli A; Moreno-Gonzalez R; Yun S; Cerda P; Llaberia M; Formiga F; Fanlo M; Montero A; Chivite D; Capdevila O; Bolao F; Pinto X; Llop J; Sabate A; Guardiola J; Cruzado JM; Comin-Colet J; Santos S; Jodar R; Corbella X
Int J Infect Dis; 2020 Dec; 101():290-297. PubMed ID: 33035673
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.
Fernández-Ruiz M; López-Medrano F; Pérez-Jacoiste Asín MA; Maestro de la Calle G; Bueno H; Caro-Teller JM; Catalán M; de la Calle C; García-García R; Gómez C; Laguna-Goya R; Lizasoáin M; Martínez-López J; Origüen J; Pablos JL; Ripoll M; San Juan R; Trujillo H; Lumbreras C; Aguado JM
J Med Virol; 2021 Feb; 93(2):831-842. PubMed ID: 32672860
[TBL] [Abstract][Full Text] [Related]
4. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
Hermine O; Mariette X; Tharaux PL; Resche-Rigon M; Porcher R; Ravaud P;
JAMA Intern Med; 2021 Jan; 181(1):32-40. PubMed ID: 33080017
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and combined use of tocilizumab and corticosteroids in a Spanish cohort of elderly COVID-19 patients.
Duarte-Millán MA; Mesa-Plaza N; Guerrero-Santillán M; Morales-Ortega A; Bernal-Bello D; Farfán-Sedano AI; García de Viedma-García V; Velázquez-Ríos L; Frutos-Pérez B; De Ancos-Aracil CL; Soria Fernández-Llamazares G; Toledano-Macías M; Cristóbal-Bilbao R; Luquín-Ciuro N; Marrero-Francés J; Piedrabuena-García SI; Satué-Bartolomé JA; Gonzalo-Pascua S; Rivilla-Jiménez M; Carpintero-García L; Ayala-Larrañaga I; García-Bermúdez V; Lara-Montes C; Llerena-Riofrío ÁR; RIvas-Prado L; Walter S; Escriba-Barcena A; San Martín López JV; Ruíz-Giardín JM
J Med Virol; 2022 Apr; 94(4):1540-1549. PubMed ID: 34845754
[TBL] [Abstract][Full Text] [Related]
6. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.
Aomar-Millán IF; Salvatierra J; Torres-Parejo Ú; Faro-Miguez N; Callejas-Rubio JL; Ceballos-Torres Á; Cruces-Moreno MT; Gómez-Jiménez FJ; Hernández-Quero J; Anguita-Santos F
Intern Emerg Med; 2021 Jun; 16(4):843-852. PubMed ID: 33400157
[TBL] [Abstract][Full Text] [Related]
7. The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers.
Rubio-Rivas M; Mora-Luján JM; Montero A; Aguilar García JA; Méndez Bailón M; Fernández Cruz A; Oriol I; Teigell-Muñoz FJ; Dendariena Borque B; De la Peña Fernández A; Fernández González R; Gil Sánchez R; Fernández Fernández J; Catalán M; Cortés-Rodríguez B; Mella Pérez C; Montero Rivas L; Suárez Fuentetaja R; Ternero Vega JE; Ena J; Martin-Urda Díez-Canseco A; Pérez García C; Varona JF; Casas-Rojo JM; Millán Núñez-Cortés J;
J Gen Intern Med; 2022 Jan; 37(1):168-175. PubMed ID: 34664188
[TBL] [Abstract][Full Text] [Related]
8. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.
Van den Eynde E; Gasch O; Oliva JC; Prieto E; Calzado S; Gomila A; Machado ML; Falgueras L; Ortonobes S; Morón A; Capilla S; Navarro G; Oristrell J; Cervantes M; Navarro M
Infect Dis (Lond); 2021 Apr; 53(4):291-302. PubMed ID: 33620019
[TBL] [Abstract][Full Text] [Related]
10. Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.
Birlutiu V; Birlutiu RM; Chicea L
Medicine (Baltimore); 2021 May; 100(18):e25832. PubMed ID: 33950993
[TBL] [Abstract][Full Text] [Related]
11. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19).
Rodríguez-Baño J; Pachón J; Carratalà J; Ryan P; Jarrín I; Yllescas M; Arribas JR; Berenguer J; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
Clin Microbiol Infect; 2021 Feb; 27(2):244-252. PubMed ID: 32860964
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis.
Fernández-Ruiz M; López-Medrano F; Carretero O; Parra P; Ruiz-Merlo T; Aguado JM;
Med Clin (Barc); 2022 Jun; 158(12):608-612. PubMed ID: 34243954
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab treatment in COVID-19: A prognostic study using propensity score matching.
Güçlü ÖA; Önal U; Akalın H; Öztürk NAA; Belik HÖ; Demirdöğen E; Dilektaşlı AG; Kazak E; Ocakoğlu G; Sağlık İ; Coşkun F; Ediger D; Heper Y; Ursavaş A; Yılmaz E; Uzaslan E; Karadağ M
Adv Clin Exp Med; 2022 Nov; 31(11):1197-1206. PubMed ID: 35951629
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India.
Dravid A; Kashiva R; Khan Z; Memon D; Kodre A; Potdar P; Mane M; Borse R; Pawar V; Patil D; Banerjee D; Bhoite K; Pharande R; Kalyani S; Raut P; Bapte M; Mehta A; Reddy MS; Bhayani K; Laxmi SS; Vishnu PD; Srivastava S; Khandelwal S; More S; Shinde R; Pawar M; Harshe A; Kadam S; Mahajan U; Joshi G; Mane D
Medicine (Baltimore); 2021 Jul; 100(29):e26705. PubMed ID: 34398044
[TBL] [Abstract][Full Text] [Related]
16. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
Galván-Román JM; Rodríguez-García SC; Roy-Vallejo E; Marcos-Jiménez A; Sánchez-Alonso S; Fernández-Díaz C; Alcaraz-Serna A; Mateu-Albero T; Rodríguez-Cortes P; Sánchez-Cerrillo I; Esparcia L; Martínez-Fleta P; López-Sanz C; Gabrie L; Del Campo Guerola L; Suárez-Fernández C; Ancochea J; Canabal A; Albert P; Rodríguez-Serrano DA; Aguilar JM; Del Arco C; de Los Santos I; García-Fraile L; de la Cámara R; Serra JM; Ramírez E; Alonso T; Landete P; Soriano JB; Martín-Gayo E; Fraile Torres A; Zurita Cruz ND; García-Vicuña R; Cardeñoso L; Sánchez-Madrid F; Alfranca A; Muñoz-Calleja C; González-Álvaro I;
J Allergy Clin Immunol; 2021 Jan; 147(1):72-80.e8. PubMed ID: 33010257
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of tocilizumab therapy in severe or critical COVID-19 patients: A retrospective cohort, single-centre study.
Abdelnaby H; Aboelhassan W; Al-Jarallah M; Rajan R; Dashti R; Zhanna KD; Alsaber AR; Abd El-Aleem A; Ashry I; Abdullah M; Mahmoud Fouad A
Trop Med Int Health; 2021 Dec; 26(12):1689-1699. PubMed ID: 34601803
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients.
Toda M; Fujii K; Yoshifuji A; Kondo Y; Itoh K; Sekine K; Kikuchi T; Ryuzaki M
Clin Exp Nephrol; 2022 Jan; 26(1):75-85. PubMed ID: 34436742
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety.
Hill JA; Menon MP; Dhanireddy S; Wurfel MM; Green M; Jain R; Chan JD; Huang J; Bethune D; Turtle C; Johnston C; Xie H; Leisenring WM; Nina Kim H; Cheng GS
J Med Virol; 2021 Apr; 93(4):2270-2280. PubMed ID: 33200828
[TBL] [Abstract][Full Text] [Related]
20. What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak.
Mehta M; Purpura LJ; McConville TH; Neidell MJ; Anderson MR; Bernstein EJ; Dietz DE; Laracy J; Gunaratne SH; Miller EH; Cheng J; Zucker J; Shah SS; Chaudhuri S; Gordillo CA; Patel SR; Guo TW; Karaaslan LE; Reshef R; Miko BA; Bathon JM; Pereira MR; Uhlemann AC; Yin MT; Sobieszczyk ME
PLoS One; 2021; 16(4):e0249349. PubMed ID: 33831046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
